Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

50.22USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$50.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
493,998
52-wk High
$63.60
52-wk Low
$13.06

Chart for

About

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA)... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $6,012.86
Shares Outstanding(Mil.): 119.73
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Exact Sciences reports qtrly loss per share of $0.23

* Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent

Oct 30 2017

Exact Sciences revenue beats on strong Cologuard volumes

Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.

Oct 30 2017

Exact Sciences revenue beats on strong Cologuard volumes

Oct 30 Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.

Oct 30 2017

BRIEF-Exact Sciences posts Q2 loss per share $0.27

* Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S

Jul 25 2017

BRIEF-Exact Sciences laboratories enters national ancillary provider participation agreement with Unitedhealthcare Insurance

* Exact Sciences Corp -Exact Sciences Laboratories entered national ancillary provider participation agreement with Unitedhealthcare Insurance for cologuard

Jul 05 2017

Competitors

  Price Chg
Quest Diagnostics Inc (DGX.N) $97.01 -0.09
Epigenomics AG (ECXn.F) €3.73 +0.03
GeneNews Ltd (GEN.TO) $0.17 --

Earnings vs. Estimates